my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfoli more
In a landmark discovery, researchers from Crucell Holland B.V. and The Scripps Research Institute, announced the identification of the first human monoclonal antibodies that appear capable of disabling all influenza B viruses. The discovery, published in the journal Science, addresses a significant more
Crucell N.V. and The Scripps Research Institute published an article in Science describing Crucell's novel anti-influenza antibody CR8020 and how it neutralizes group 2 influenza A viruses. Attempts to isolate broadly neutralizing antibodies against group 2 viruses have not been previously described more
Bioceros B.V. announced the extension of the non-exclusive STAR® research license agreement with Crucell. The license agreement with the Netherlands based company Bioceros covers the production of monoclonal antibodies. In addition, the extension of the agreement now includes the right for Bioceros more
This commentary offers an overview of some current trends of the pharmaceutical industry drawing on examples taken from the analysis of four companies (Pfizer, Merck, Novo Nordisk, Crucell). The very brief analysis looks at diversification paths, pipeline management strategies, generic competition a more
Introduction GlobalData, the industry analysis specialist, has released its new report, “Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Hepatitis A Preventive Vaccines market. The repo more
Are you looking for influenza vaccine market data - answers to benefit your work? Our new report shows you revenue prospects for the manufacture and sale of influenza vaccines from 2009 to 2021. There, you will see commercial opportunities for influenza vaccines - original research, data and opini more
Do you want to find market prospects for products and companies in the biological drugs industry? Our new report shows you biopharma revenue forecasts for 2011 to 2021. We provide original research, data and opinions to benefit your work now. What revenues will biopharmaceutical markets achieve fro more
Home | Company | Technology | Products | Investors | Business Development | Infocenter Search History Founders Management BOSD Scientific Adv. Board Medical Adv. Board Careers DNA-repair and Aging Publications IP Pharmaceutical Non-Pharma Shareholders Press announcements Links Contact Informatio more
worldwide offices | stay connected | contact | help | sitemap Home Products Products home Pharmaceuticals Vaccines and Diagnostics Sandoz (Generics) Over-the-Counter Animal Health CIBA Vision Diseases & Conditions R&D R&D home Drug discovery and development process Novartis Institutes for more
Kenta's management team has a proven track record in the research, and commercialisation development of biotech products. It is backed by an experienced Board of Directors. About Kenta Biotech Strategy Management Board of Directors Advisory Boards » english » german » imprint Dr. Kuno Somm more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
